Active Ingredient: Respiratory syncytial virus vaccine
mRNA-based vaccine is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus in adults 60 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
For this indication, competent medicine agencies globally authorize below treatments:
For:
In case that patient age in years is ≥ 60
Intramuscular, 0.5 milliliters respiratory syncytial virus vaccine, one dose.
The recommended dose of the mRNA-based vaccine is one single dose of 0.5 mL.
The mRNA-based vaccine should be administered preferably in the deltoid muscle of the upper arm. The injection should be given using standard aseptic technique.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.